ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESMMAKHTNMDGE........*X0009010-RPUB024770752A120260708EP24773576.42024082720260303enenen202363579070 P20230828US2026070820262820260708202628A61P 31/20 20060101AFI20250307BHEP A61K 31/496 20060101ALI20250307BHEP C07D 417/04 20060101ALI20250307BHEP C07D 417/04 20130101 FI20241106BHEP A61P 31/20 20180101 LI20241106BHEP A61K 31/513 20130101 LI20250207BHEP A61K 45/06 20130101 LI20250207BHEP A61P 31/22 20180101 LI20250207BHEP deKRISTALLINE FORM VON 2-(3-(2,5'-DIFLUOR-[1,1'-BIPHENYL)-4-YL)-2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)-4-METHYLTHIAZOL-5-SULFONAMIDenA CRYSTALLINE FORM OF 2-(3-(2,,5'-DIFLUORO-[1,1'-BIPHENYL]-4-YL)-2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)-4-METHYLTHIAZOLE-5-SULFONAMIDEfrNOUVELLE FORME CRISTALLINE DE 2-(3-(2,,5'-DIFLUORO-[1,1'-BIPHÉNYL]-4-YL)-2-OXOTÉTRAHYDROPYRIMIDIN-1(2H)-YL)-4-MÉTHYLTHIAZOLE-5-SULFONAMIDEAssembly Biosciences, Inc.102085152P092219EPTwo Tower Place, 7th FloorSouth San Francisco, CA 94080USZONG, ZhixinSan Francisco, California 94080USWU, YiSan Francisco, California 94080USCarpmaels & Ransford LLP101299776One Southampton RowLondon WC1B 5HAGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMEMKMTNLNOPLPTRORSSESISKSMTRBA20260303GE20260303KH20260303MA20260303MD20260303TN20260303IB202405830920240827enWO202504645620250306202510